Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.

Tolani B, Acevedo LA, Hoang NT, He B.

Int J Mol Sci. 2018 Jan 13;19(1). pii: E238. doi: 10.3390/ijms19010238. Review.

2.

Sialic acid-binding lectin from bullfrog eggs inhibits human malignant mesothelioma cell growth in vitro and in vivo.

Tatsuta T, Satoh T, Sugawara S, Hara A, Hosono M.

PLoS One. 2018 Jan 3;13(1):e0190653. doi: 10.1371/journal.pone.0190653. eCollection 2018.

3.

Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis.

Cerruti F, Jocollè G, Salio C, Oliva L, Paglietti L, Alessandria B, Mioletti S, Donati G, Numico G, Cenci S, Cascio P.

Sci Rep. 2017 Dec 15;7(1):17626. doi: 10.1038/s41598-017-17977-9.

4.

Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity.

Tan Y, Sementino E, Chernoff J, Testa JR.

Am J Cancer Res. 2017 Aug 1;7(8):1724-1737. eCollection 2017.

5.

Novel systemic therapy against malignant pleural mesothelioma.

Mancuso MR, Neal JW.

Transl Lung Cancer Res. 2017 Jun;6(3):295-314. doi: 10.21037/tlcr.2017.06.01. Review.

6.

Malignant Pleural Mesothelioma with Marked Lymphatic Involvement: A Report of Two Autopsy Cases.

Ideguchi R, Ashizawa K, Akashi S, Shindo M, Minami K, Fukuda T, Irie J, Fukuda M, Uetani M.

Case Rep Oncol Med. 2017;2017:6195898. doi: 10.1155/2017/6195898. Epub 2017 May 29.

7.

Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists.

Urso L, Cavallari I, Silic-Benussi M, Biasini L, Zago G, Calabrese F, Conte PF, Ciminale V, Pasello G.

Oncotarget. 2017 Jul 4;8(27):44232-44241. doi: 10.18632/oncotarget.17790.

8.

Synergistic anti-tumor effect of bullfrog sialic acid-binding lectin and pemetrexed in malignant mesothelioma.

Satoh T, Tatsuta T, Sugawara S, Hara A, Hosono M.

Oncotarget. 2017 Jun 27;8(26):42466-42477. doi: 10.18632/oncotarget.17198.

9.

Spatial and molecular resolution of diffuse malignant mesothelioma heterogeneity by integrating label-free FTIR imaging, laser capture microdissection and proteomics.

Großerueschkamp F, Bracht T, Diehl HC, Kuepper C, Ahrens M, Kallenbach-Thieltges A, Mosig A, Eisenacher M, Marcus K, Behrens T, Brüning T, Theegarten D, Sitek B, Gerwert K.

Sci Rep. 2017 Mar 30;7:44829. doi: 10.1038/srep44829.

10.

Modern management of malignant pleural mesothelioma.

Patel SC, Dowell JE.

Lung Cancer (Auckl). 2016 May 3;7:63-72. doi: 10.2147/LCTT.S83338. eCollection 2016. Review.

11.

Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia.

Zonca S, Pinton G, Wang Z, Soluri MF, Tavian D, Griffin M, Sblattero D, Moro L.

Cell Death Dis. 2017 Feb 2;8(2):e2592. doi: 10.1038/cddis.2017.30.

12.

Improvement of Malignant Pleural Mesothelioma Prognosis: Early Diagnosis and Multimodality Treatment.

Ban CJ, Shi HZ, Zhang YH.

Chin Med J (Engl). 2017 5th Jan 2017;130(1):1-3. doi: 10.4103/0366-6999.196585. No abstract available.

13.

MicroRNA-302b targets Mcl-1 and inhibits cell proliferation and induces apoptosis in malignant pleural mesothelioma cells.

Khodayari N, Mohammed KA, Lee H, Kaye F, Nasreen N.

Am J Cancer Res. 2016 Sep 1;6(9):1996-2009. eCollection 2016.

14.

Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response.

Zhang J, Khanna S, Jiang Q, Alewine C, Miettinen M, Pastan I, Hassan R.

Clin Cancer Res. 2017 Mar 15;23(6):1564-1574. doi: 10.1158/1078-0432.CCR-16-1667. Epub 2016 Sep 15.

PMID:
27635089
15.

MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients.

Lin RC, Kirschner MB, Cheng YY, van Zandwijk N, Reid G.

Genom Data. 2016 Jun 20;9:44-9. doi: 10.1016/j.gdata.2016.06.009. eCollection 2016 Sep.

16.

Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines.

Monica V, Lo Iacono M, Bracco E, Busso S, Di Blasio L, Primo L, Peracino B, Papotti M, Scagliotti G.

Oncotarget. 2016 Nov 22;7(47):76577-76589. doi: 10.18632/oncotarget.10428.

17.

Role of respiratory-triggered diffusion-weighted MRI in the assessment of pleural disease.

Revelli M, Chiesa F, Del Prato A, Tagliafico A, Rosenberg I, Canessa PA, Pinelli V, Villa A.

Br J Radiol. 2016 Jun 29:20160289. [Epub ahead of print]

18.

KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.

Cheng YY, Wright CM, Kirschner MB, Williams M, Sarun KH, Sytnyk V, Leshchynska I, Edelman JJ, Vallely MP, McCaughan BC, Klebe S, van Zandwijk N, Lin RC, Reid G.

Mol Cancer. 2016 Jun 1;15(1):44. doi: 10.1186/s12943-016-0529-z.

19.

Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma.

Lennon FE, Cianci GC, Kanteti R, Riehm JJ, Arif Q, Poroyko VA, Lupovitch E, Vigneswaran W, Husain A, Chen P, Liao JK, Sattler M, Kindler HL, Salgia R.

Sci Rep. 2016 Apr 15;6:24578. doi: 10.1038/srep24578.

20.

Anaesthetic management of extra-pleural pneumonectomy and hyperthermic intrathoracic chemotherapy procedure.

Ramegowda JK, Salam MA, Nayak V, Zaveri S.

Indian J Anaesth. 2015 Dec;59(12):807-10. doi: 10.4103/0019-5049.171574.

Supplemental Content

Support Center